Jinyu Medical recently disclosed that the semi-annual report data showed that the operating income in the first half of 2018 was 2,114,650,100 yuan, a year-on-year increase of 17.55%, and the net profit attributable to shareholders of listed companies was 95,767,700 yuan, a year-on-year increase of 14 .14%.
In the first half of 2018, Jinyu Medical achieved breakthroughs in resource integration and medical construction platforms.
(1) Joining the team of China's famous kidney disease expert and academician of the Chinese Academy of Sciences Hou Fanfan to establish the National Chronic Nephrology Clinical Medical Research Center Jinyu Medical Kidney Pathology Center and the Guangdong Provincial Institute of Nephrology - Jinyu Medical College workstation to improve the kidney disease in China Diagnostic and technical service level and the development of chronic kidney disease prevention and treatment in China.
(2) In the blood flow cytometry test, new projects such as screening and evaluation of highly sensitive hematological tumor minimal residual disease (MRD) markers were successfully carried out in the first half of the year, and successfully passed the UK National External Quality Assessment Program (UKNEQAS). At present, it has been used in many multi-center clinical trials of blood tumors nationwide.
(3) In the first half of the year, the expansion of the field of gene sequencing was initiated, and the global gene sequencing giant Illumina cooperated to develop an integrated next-generation sequencing (NGS) system for Chinese patients and provide a new application method for tumor and genetic disease testing.
(4) Build a comprehensive digital pathology management system, provide a common platform for artificial intelligence pathology-assisted diagnosis industry and product development, and continuously organize and improve the pathological data and pathological image annotation information, and establish a large-scale digital pathology case database and annotation information base. The company focused on the use of artificial intelligence to assist pathological diagnosis, preliminary exploration of AI cervical cytology screening, AI immunohistochemical pattern semi-quantitative analysis, AI tissue tumor classification, etc., to promote the development of precision pathology diagnosis and testing in the direction of intelligence.
(5) The investment and participation of the South China Biomaterials Entry and Exit Public Service Platform was officially unveiled. Guangzhou Jinjing Biomaterials Logistics Service Co., Ltd., a joint venture established by the company and Guangzhou International Bio Island Technology Investment Development Co., Ltd., undertakes the operation and service of the platform. The improvement of bio-energy clearance and supervision level will reduce the operating costs of bio-enterprises and accelerate the development of bio- and health industries.
(6) Complete the 4th generation core production management system KMCS independently researched and developed by all subsidiaries. It adopts advanced IT technology and integrates information flow, logistics, cash flow, operation flow and service flow to cover customer service and sales. It examines the end-to-end full-cycle closed-loop management, covering the entire process from receiving specimens to inspecting specimens to reporting output, and capable of carrying 1 million-level daily specimens. The company independently researched and developed the regional cooperation and co-construction system KMLIS, and provided information solutions for various forms of cooperation and co-construction of hospitals; completed the “Kidney Specialized Case Management Systemâ€, providing medical knowledge management and specialist communication for the Association of Nephrology Specialists. , case data, inspection orders, logistics services and other functions, comprehensive support with a "customer-centric, clinical and disease-oriented" strategy.
Functional oligosaccharides refer to oligosaccharides that are difficult or impossible to be digested and absorbed by the human body and have special physiological effects on the human body. Its sweetness is generally only 30-50% of that of sucrose, and it has physiological functions such as low-calorie, anti-caries, prevention and treatment of diabetes, and improvement of intestinal colony structure. Due to the special physiological functions of functional oligosaccharides, it becomes a nutrient and health care product. A new generation of food-effect raw materials that integrate diet and therapy. It is a new functional sugar source that replaces sucrose and has a wide range of uses and application prospects. Common functional oligosaccharides include: xylo-oligosaccharides, fructooligosaccharides, galacto-oligosaccharides, isomaltose, raffinose and so on.
XOS, GOS, FOS, IMO, Raffinose, oligosaccharide
Xi'an Gawen Biotechnology Co., Ltd , https://www.ahualyn-bios.com